In a powerful Wall Street Journal essay, retired internal-medicine physician Brent Beasley recounts how he discovered—almost by accident—that he had Alzheimer’s disease at age 57. His story is not just personal. It is an indictment of a U.S. health care system that waits for crisis instead of preventing it.
Beasley wasn’t diagnosed because the system worked. He was diagnosed despite it.
“Diagnosing Alzheimer’s early is like finding stage one cancer rather than stage four.”
Even with decades of medical experience and a supportive spouse, it took Beasley nearly a year to receive a confirmed diagnosis. By then, many patients would already be past the point where intervention can meaningfully slow the disease.
That delay is not a medical inevitability. It is a policy failure.
Early Detection Exists. Access Does Not.
Today, blood-based biomarker tests like p-tau217 can identify Alzheimer’s before irreversible brain damage occurs. Early diagnosis opens the door to lifestyle interventions, caregiver planning, and—when appropriate—FDA-approved therapies that can preserve independence and cognitive function.
Up to 40% of dementia cases are preventable or can be delayed when caught early.
Yet the system remains structured around late-stage care. Primary-care physicians are not empowered—or incentivized—to routinely screen cognition. Patients are referred to specialists with months-long waits. Insurance companies question whether approved treatments are “worth it,” even when they are working.
“If it was difficult for me, a physician with a dedicated spouse, to get diagnosed in time, imagine how hard it can be for others.”
Crisis Care Is More Expensive Than Prevention
Alzheimer’s is already one of the largest and fastest-growing drivers of Medicare and Medicaid spending. Delaying diagnosis doesn’t save money—it accelerates costs by pushing patients into institutional care sooner and removing them from the workforce earlier.
Beasley’s experience shows what is possible when intervention happens in time.
“After nine months of treatment, I vividly recall a church service where I knew exactly where I was and what I was supposed to do. Afterward, I told my wife, ‘I’m back.’”
That outcome is not just meaningful for families—it has enormous economic implications.
What Policy Should Do Next
Beasley’s conclusion aligns with what reformers have long argued: Alzheimer’s policy must move upstream.
That means:
- Expanding access to early, affordable blood-based diagnostic tests
- Ensuring insurance coverage for FDA-approved therapies once patients qualify
- Empowering primary-care doctors to detect and manage Alzheimer’s earlier
- Supporting caregivers so patients can remain at home longer
Without these changes, scientific breakthroughs will remain out of reach for most families—while public costs continue to soar.
Alzheimer’s does not have to be a late-stage crisis. But without policy reform, it will remain one.
Read Dr. Beasley’s full account at the Wall Street Journal by clicking here.
